Who Paid My Doc
A Phase 4 Randomized Double-Blind Placebo Controlled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Subjects with Cardiovascular Contraindication to Triptans High Cardiovascular Risk or Triptan Resistant Subjects
Research payments
$106,305
Through program year 2022, $106,305 in research payments was reported against A Phase 4 Randomized Double-Blind Placebo Controlled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Subjects with Cardiovascular Contraindication to Triptans High Cardiovascular Risk or Triptan Resistant Subjects, across 39 payments, paid by Biohaven Pharmaceutical Holding Company Ltd..
- Paid by
- Biohaven Pharmaceutical Holding Company Ltd.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $106,305 | 39 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- David True Springfield, MO Named on 8 payments
- Haydn Thomas Prairie Village, KS Named on 7 payments
- Guy Strauss Lake City, FL Named on 5 payments
- Harvey Resnick Lake Jackson, TX Named on 4 payments
- Patrick Dennis New Orleans, LA Named on 4 payments
- Antonio Mendes Roslindale, MA Named on 3 payments
- Celia Brown Woodland Hills, CA Named on 2 payments
- Muhammad Irfan Tomball, TX Named on 2 payments
- Timothy Smith Saint Peters, MO Named on 2 payments
- Brittany Newton Daytona Beach, FL Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.